Raltegravir
0518-851
Approved small_molecule completed
Quick answer
Raltegravir for Human Immunodeficiency Virus (HIV) Infection is a Approved program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Human Immunodeficiency Virus (HIV) Infection
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed